Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P)
Status:
Not yet recruiting
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
This trial is a prospective, multi-center, randomized comparison study of 2 Pre-Exposure
Prophylaxis (PrEP) pharmacokinetic (PK) dosing regimens from 1st trimester through 12 weeks
following delivery (postpartum) to achieve study objectives which include PK, safety
monitoring for maternal and fetal/infant safety signals, and adherence.
Phase:
Phase 1
Details
Lead Sponsor:
Johns Hopkins University
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir